Rocket制药 RCKT 深 沪
已收盘 07-02 16:00:00 美东时间
3.84
+0.320
+9.09%
华盛通- 最 高3.85
- 今 开3.52
- 成交量 270.19万股
- 最 低 3.52
- 昨 收 3.52
- 总市值 4.19亿
- 52周最高 5.45
- 市盈率 静 --
- 换手率 2.47%
- 52周最低 2.53
- 委 比 34.97%
- 总股本 1.09亿
- 历史最高 67.48
- 量 比 0.86
- 振 幅 9.38%
- 历史最低 2.19
- 每 手 1
- 风险率 0.50%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多9 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers American Shared Hospital (AMEX:AMS) stock rose 14.2% to $1.61 during Wednesday's after-market session. The market value of their outstanding shares is at $9.7 million. Greenland Mines (NASDAQ:GRML) stock moved upwards by 7.18% to $0.24. The company's market cap stands at $34.7 million. Lunai...
06-25 05:05
Rocket Pharma updates cash position after selling priority review voucher
Rocket Pharmaceuticals (RCKT) on Friday disclosed more than $320M in cash, cash equivalents, and investments pro forma after completing the previously disclosed sale of its rare pediatric disease prio...
06-12 19:31
Rocket Pharmaceuticals Closes Sale Of Its Rare Pediatric Disease Priority Review Voucher For Gross Proceeds Of $180M
The Rare Pediatric Disease Priority Review Voucher was granted by the FDA in March 2026 in connection with the approval of KRESLADI™, Rocket's gene therapy for severe leukocyte adhesion deficiency-I (LAD-I), a rare and life-threatening primary immunodeficiency. As previously reported, before the PRV...
06-12 19:02
Rocket Pharmaceuticals sells rare pediatric disease priority review voucher for $180 million
Rocket Pharmaceuticals sells rare pediatric disease priority review voucher for $180 million Rocket Pharmaceuticals closed the sale of its Rare Pediatric Disease Priority Review Voucher for gross proceeds of USD 180 million. The voucher was awarded in March 2026 tied to the FDA approval of KRESLADI
06-12 19:00
Rocket Pharmaceuticals Q1 EPS $(0.42) Beats $(0.43) Estimate
Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.43) by 2.33 percent. This is a 25 percent increase over losses of $(0.56) per share
05-08 04:24
US FDA's accelerated approval for drugs needs more transparency, says research firm
US FDA's accelerated approval for drugs needs more transparency, says research firm By Sneha S K April 16 (Reuters) - The U.S. Food and Drug Administration should be more transparent when granting accelerated approval for certain drugs, influential drug pricing body, Institute for Clinical and Econo
04-16 20:00
美股大行评级 | 潜在涨幅172.14%！Alumis获Oppenheimer上调目标价至55美元；摩根大通首予希捷科技"超配"评级，目标价525美元
今日重点评级关注：Oppenheimer：维持Alumis"跑赢大市"评级，目标价从50美元升至55美元；美银证券：维持Rocket Pharmaceuticals"买入"评级，目标价从8美元升至9美元
03-31 16:30
BUZZ-U.S. STOCKS ON THE MOVE-Alphabet, Phathom, Argan
BUZZ-U.S. STOCKS ON THE MOVE-Alphabet, Phathom, Argan Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 March 27 (Reuters) - Wall Street's main indexes were on track to open lower
03-27 21:15
Why Is Rocket Pharma Stock Soaring Friday?
Rocket Pharmaceuticals stock jumps after FDA nod for Kresladi in LAD-I; voucher sale may boost cash runway and support growth plans.
03-27 21:13
